Document is current

Article History

Received: 23 August 2023

Revised: 25 August 2023

Accepted: 4 September 2023

First Online: 21 September 2023

Competing interests

: Author PMK reports grants paid to the institution by Merck, Agenus Bio, Novartis, Advanced Accelerator Applications, Tersera, and Boston Scientific; a consultancy and advisory board relationship with Elicio (scientific advisory board member/shares/stock ownership); consultancy/advisory board fees from Guardant Health, Natera, Foundation Medicine, Illumina, BostonGene, Merck/MSD Oncology, Tempus, Bayer, Lilly, Delcath Systems, IPBA, QED Therapeutics, Boston Healthcare Associates, Servier, Taiho Oncology, Exact Sciences, Daiichi Sankyo/AstraZeneca, Eisai, Saga Diagnostics, Neogenomics, Do More Diagnostics AS, and Seattle Genetics; consulting fees paid to the institution by Taiho Pharmaceutical and Ipsen; receiving travel support from AstraZeneca for presentation of an investigator initiated trial. All other authors report no COIs. MH is a member of the board of directors for Bristol Myers Squibb; is a founder of Champions Oncology, Inc., and Nelum Inc.; holds stock options for Champions Oncology, Inc.; InxMed; Biooncotech; and Bristol Myers Squibb; has received research support from Agenus; has received honoraria from InxMed, Oncomatrix, MiNKi, and Peaches Biotech; and has received royalties from Myriad and Khar. MDJ has received honorarium as a speaker for Covidien. A.P. has received honorarium as a consultant for Medtronic, Vioptix, Ethicon, and Intuitive. MAS reports receiving research funding from Astellas Pharma Inc., Merck, Bristol Myers Squibb and Oncolys BioPharma and serving a leadership or judiciary role in board, society, committee or advocacy groups for the American Society of Clinical Oncology Leadership Council. U.K. reports honoraria and travel/accommodations from Cardinal Health, and 2nd.MD. DS reports consultancy for Ciox Health and Zephyr AI, Inc., and speaker/lecturer for Natera, Inc. AJO discloses royalties from Guardant Health and Natera. All other authors have no declared competing interests or financial ties to disclose.